Enhanced Benefit Can Deliver Significant Health and Economic Value by Targeting Chronic Inflammation
WALTHAM, MA – February 23, 2017 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on the genetics of chronic inflammation, announced today that it has entered into a relationship with mPulse Mobile, a leader in mobile health engagement, to offer the ILUSTRA Inflammation Management Program to their employees as an enhancement to the company’s employee benefits plan.
“This innovative program is a clear match with our company values and mission,” said Brian Chudleigh, Chief Financial Officer at mPulse Mobile. “Affecting behavioral change toward a healthy lifestyle is the key to realizing long-term health, wellness and reduced healthcare costs. I am impressed with the ILUSTRA program in how it utilizes both genetic insights to identify risk and engagement tactics to empower change.”
The ILUSTRA Inflammation Management Program targets individuals with elevated risk for severe periodontitis due to a genetic tendency to over-produce inflammation and directs them to obtain proper dental care. The program integrates three critical components: 1) a genetic risk test to identify patients at risk; 2) targeted education to healthcare professionals to individualize employee care plans; and 3) an 18-month subscription to the ILUSTRA Engagement Platform – a digital program that delivers engaging, personalized content tailored to maximize engagement and drive compliance and behavior change.
Several studies link oral and systemic disease and document the significant impact of enhanced dental care to lower costs of medical management of certain chronic diseases like type 2 diabetes, cardiovascular disease and stroke. ILUSTRA is a proprietary program that has the potential to transform inflammation management by optimizing access to dental care to impact the onset and the progression of chronic diseases, and thereby reducing employer healthcare costs.
“mPulse Mobile epitomizes a company at the forefront of wellness innovation,” said Mark Carbeau, Chief Executive Officer of Interleukin Genetics. “I’m very proud of our growing relationship with such forward-thinking leaders and we believe that our association with mPulse Mobile will both provide significant value to their employees and advance our commercial agenda with ILUSTRA.”
About the ILUSTRA Inflammation Management Program
The ILUSTRA Inflammation Management Program is designed to transform the management of inflammation. The program utilizes a genetic test to identify patients at elevated risk for developing severe periodontal disease due to a genetic tendency to over-produce inflammation. Such individuals may benefit from enhanced dental care to lower their systemic inflammatory burden by preventing and treating gingivitis and periodontitis. The program integrates educational outreach to the patient’s care team and provides reminders and content to patients to drive engagement. The ILUSTRA Inflammation Management Program is made available to employees in covered health plans under the supervision of a licensed dentist or physician. The ILUSTRA test is run solely in Interleukin’s CLIA-certified lab in suburban Boston. For more information, visit www.ILUSTRA.com.
About mPulse Mobile
mPulse Mobile, a leader in mobile health engagement, drives improved health outcomes and business efficiencies by engaging individuals with meaningful and interactive dialog. mPulse Mobile combines technology, analytics and industry expertise that helps healthcare organizations activate their customers to adopt healthy behaviors. With over 8 years, a hundred million messages sent, and 50+ Health Plan, Provider, Pharma and Wellness customers, mPulse Mobile has the data, the experience and the technology to drive healthy behavior change.
About Interleukin Genetics, Inc.
Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic inflammatory diseases and health-related conditions, with significant expertise in metabolism and inflammation. Our tests provide information that is not otherwise available, to empower individuals and their healthcare providers to manage their health and wellness through genetics-based insights and actionable guidance, including pharmacogenomics information to guide development and use of therapeutics. Interleukin Genetics’ lead products include its proprietary ILUSTRA Inflammation Management Program, an integrated program that utilizes a simple genetic test to easily identify patients at elevated risk for developing severe periodontal disease due to a genetic tendency to over-produce inflammation; its cardiovascular test to guide treatment of high risk patients; and its Inherent Health® line of genetic tests. Interleukin Genetics is headquartered in suburban Boston and operates an on-site DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit www.ilgenetics.com.
Certain statements contained herein are “forward-looking” statements, including, but not limited to, statements that our ILUSTRA Inflammation Management Program has potential to provide significant health and economic value by improving the management of chronic inflammation; that certain individuals may benefit from enhanced dental care to lower their systemic inflammatory burden by preventing and treating gingivitis and periodontitis; and the benefits our relationship with mPulse Mobile will bring to mPulse Mobile and its employees and Interleukin. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in Interleukin’s annual report on Form 10-K for the year ended December 31, 2015, and other filings with the Securities and Exchange Commission. Interleukin disclaims any obligation or intention to update these forward-looking statements.
Interleukin Genetics, Inc.
Interleukin Genetics, Inc.